G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Conference Call February 28, 2024 8:30 AM ET

Company Participants

Will Roberts - VP-Communications

Jack Bailey - CEO

Andrew Perry - CCO

Raj Malik - CMO

John Umstead - CFO

Conference Call Participants

Joseph Thome - TD Cowen

Gil Blum - Needham Company

Priyanka Grover - JPMorgan

Laura Prendergast - Raymond James

Operator

Good day, and thank you for standing by. Welcome to the G1 Therapeutics Fourth Quarter 2023 Financial Reference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your first speaker today, Will Roberts, Corporate Communications. Please go ahead.

Will Roberts

Thank you, Rica. Good morning, everyone, and welcome to the G1 conference call to discuss our fourth quarter and full year 2023 financial results and business update. The press release on these financial results was issued this morning and can be found in the news section of our corporate website, g1therapeutics.com.

On this morning's call, the team will provide a business overview of the 2023 fourth quarter and full year, including an update on our clinical programs and our commercial progress in that period with COSELA, which is approved and commercially available to decrease the incidence of chemotherapy-induced myelosuppression in adult patients who were administered prior to a platinum etoposide containing regimen or topotecan containing regimen for extensive stage small cell lung cancer.

As Rica commented, the Q&A session will follow the prepared remarks. Before we begin, I want to remind you that today's webcast contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements represent management's judgment as of today and may involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by these statements.

For more information on such risks and uncertainties, please refer to our filings with the Securities and Exchange Commission, which are available from the SEC or on our corporate website. Any forward-looking statements represent our views as of today, February 28, 2024.

Joining me on the call today are Jack Bailey, our Chief Executive Officer; Andrew Perry, our Chief Commercial Officer; Raj Malik, our Chief Medical Officer; and John Olmsted, our Chief Financial Officer.

With that, I'll turn the call over to Jack.

Jack Bailey

Thanks, Will. Good morning, everyone, and thank you for joining us on the call today.